Welcome to our dedicated page for Nurix Therapeutics news (Ticker: NRIX), a resource for investors and traders seeking the latest updates and insights on Nurix Therapeutics stock.
Nurix Therapeutics, Inc. reports developments as a clinical-stage biopharmaceutical company developing targeted protein degradation medicines for oncology and autoimmune and inflammatory diseases. News commonly centers on bexobrutideg (NX-5948), a Bruton’s tyrosine kinase degrader, including clinical data in chronic lymphocytic leukemia, small lymphocytic lymphoma and Waldenström macroglobulinemia, as well as updates tied to the DAYBreak development program.
Company updates also cover Nurix’s DEL-AI discovery platform, preclinical degrader programs against targets such as pan-mutant BRAF, CBL-B and Aurora kinase A, and partnered inflammation and immunology programs involving IRAK4 and STAT6 degraders. Recurring announcements include financial results, corporate presentations, scientific meeting data, pipeline progress, capital actions and board or governance changes.
Nurix Therapeutics (Nasdaq: NRIX) announced that Arthur T. Sands, M.D., Ph.D., will participate in two significant conferences in September 2022. The presentations include a Fireside chat at the Wells Fargo Healthcare Conference on September 7 from 3:45 to 4:15 p.m. ET, and another at the Baird 2022 Global Healthcare Conference on September 13 from 10:50 to 11:20 a.m. ET. These events will be webcast live, with recordings available for approximately 30 days. Nurix specializes in targeted protein modulation for treating cancer.
Nurix Therapeutics (Nasdaq: NRIX) announced the appointment of Eric Schlezinger as Chief People Officer. With extensive experience in biopharma HR, Schlezinger aims to enhance leadership and talent acquisition as Nurix expands its oncology pipeline. CEO Arthur Sands highlighted Schlezinger's strengths in building company culture and recruiting top talent. Previously, Schlezinger led HR at Adamas Pharmaceuticals and Vir Biotechnology, contributing to their growth and transitions to public companies. Nurix focuses on targeted protein modulation for cancer treatment, utilizing E3 ligases in their drug discovery.
Nurix Therapeutics (Nasdaq: NRIX) announced a registered direct offering of pre-funded warrants to purchase 2,869,440 shares of common stock at a price of $13.939 per warrant, raising approximately $40 million. The transaction with two healthcare-focused investment funds is expected to close on July 11, 2022. Proceeds will support clinical trials, manufacturing, and research, allowing Nurix to fund operations into the second half of 2024. The offering is conducted under an effective shelf registration statement and will not constitute an offer to sell securities in any unlawful jurisdiction.
Nurix Therapeutics (Nasdaq: NRIX) announced a registered direct offering of pre-funded warrants to purchase 3,945,480 shares of common stock at $13.939 per warrant, totaling approximately $55 million in gross proceeds. The offering is expected to close on July 11, 2022. Proceeds will support clinical trials, manufacturing, research, and other corporate purposes, aiming to fund operations into the second half of 2024. The financing includes participation from Redmile Group. The pre-funded warrants were offered under a previously filed shelf registration statement with the SEC.
Nurix Therapeutics, Inc. (NRIX) announced advancements in its clinical programs, including the initiation of Phase 1b for NX-2127 in chronic lymphocytic leukemia (CLL) due to promising Phase 1a results. The first patient was dosed in the Phase 1a trial for NX-5948 targeting B-cell malignancies. Financially, collaboration revenue rose to $11.4 million, driven by partnerships with Gilead and Sanofi. However, the net loss increased to $45.4 million for Q2 2022. As of May 31, 2022, cash and investments stood at $348.8 million.
Nurix Therapeutics (Nasdaq: NRIX) has received FDA clearance for its Investigational New Drug (IND) application to expand its NX-1607 Phase 1 clinical program into the U.S. Previously enrolling patients in the U.K., this trial will assess the safety and tolerability of NX-1607, a first-in-class CBL-B inhibitor targeting advanced malignancies.
The company aims to share initial biomarker data from the trial in the latter half of 2022, highlighting its commitment to developing innovative therapies for solid tumors.
Nurix Therapeutics (Nasdaq: NRIX) presented details about its Phase 1 clinical trials for NX-2127 and NX-5948 at the EHA2022 Hybrid Congress held from June 9-12, 2022. Both investigational therapies target patients with relapsed and refractory B-cell malignancies. Initial results from NX-2127 show clinically meaningful degradation of BTK in all patients, including those with mutations causing resistance to standard care. Further data is expected in the latter half of 2022. Posters are available for on-demand viewing on the EHA website.
Nurix Therapeutics (Nasdaq: NRIX) announced the presentation of clinical trial designs for its three investigational therapies: NX-2127, DeTIL-0255, and NX-1607 at the ASCO Annual Meeting from June 3-7, 2022. NX-2127 targets relapsed/refractory B-cell malignancies, DeTIL-0255 is focused on advanced gynecologic tumors, and NX-1607 aims to enhance anti-tumor immunity in solid tumors. Initial data from NX-2127 demonstrated significant BTK degradation. Additional data is expected in H2 2022.
Nurix Therapeutics (Nasdaq: NRIX) has initiated Phase 1b expansion cohorts of its ongoing trial for NX-2127, a BTK degrader, focusing on patients with chronic lymphocytic leukemia (CLL). This decision follows promising results from the Phase 1a study, revealing significant clinical benefits in heavily pre-treated patients. Key findings include confirmed responses in patients resistant to current therapies and robust BTK degradation. The R&D Day on May 26 will detail further data and future plans for NX-2127, which aims to address unmet needs in cancer treatment.
Nurix Therapeutics (Nasdaq: NRIX) announced the dosing of the first patient in its Phase 1a/1b trial for NX-5948, a selective degrader of Bruton’s tyrosine kinase (BTK), targeting relapsed B-cell malignancies. This open-label, dose escalation trial is ongoing across multiple UK centers, focusing on safety and tolerability. Initial data is expected in H2 2022. NX-5948 aims to address resistance seen with current BTK inhibitors. Nurix has four clinical trials running, with upcoming data catalysts anticipated over the next year.